Related Experiment Videos
[Efficacy and tolerability of a delayed-action vasodilator agent, cadralazine, in severe chronic cardiac failure]
Insights
This study evaluated cadralazine, a new arterial vasodilator, in patients with severe cardiac insufficiency. Cadralazine significantly improved cardiac index and reduced systemic resistance, indicating potential therapeutic benefits.
Area of Science:
- Cardiovascular pharmacology
- Hemodynamics
- Clinical trial design
Context:
- Severe cardiac insufficiency presents significant therapeutic challenges.
- Arterial vasodilators are crucial for managing heart failure.
- Evaluating novel vasodilators like cadralazine is essential for advancing treatment options.
Purpose:
- To assess the hemodynamic effects of cadralazine in patients with severe cardiac insufficiency.
- To determine the safety and efficacy of single-dose cadralazine administration.
- To evaluate changes in cardiac index, arterial pressures, and ventricular power.
Summary:
- A single administration of cadralazine (30 mg and 60 mg) was evaluated in 12 patients with severe cardiac insufficiency.
- No significant changes were observed in cardiac frequency or pulmonary artery pressures.
- Significant increases in cardiac index and left ventricular power, along with a decrease in total systemic resistance, were noted 8 hours post-administration of 30 mg cadralazine.
Impact:
- Cadralazine demonstrates potential as an effective arterial vasodilator for severe cardiac insufficiency.
- The findings suggest a favorable hemodynamic profile for cadralazine, particularly regarding cardiac output and systemic vascular resistance.
- Further research may explore optimal dosing and long-term effects of cadralazine in heart failure management.
Abstract:
The aim of this work is the evaluation of the hemodynamic effects during the 24 hours following a single administration of a new arterial vasodilator, cadralazine, in 12 patients whose mean age is 66 years and who present severe cardiac insufficiency. A clinical and hemodynamic examination was made before administration of the medicine in 3 doses at 12 hour intervals in order to check the stationary state of the patients, and then at 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 20 h and 24 h after 30 mg, and then 60 mg of cadralazine. We did not observe any significant change in cardiac frequency, nor in the systolic arterial pressure nor in the diastolic arterial pressure of the pulmonary artery, after either 30 mg or 60 mg. On the other hand, with 30 mg of cadralazine we observed a significant increase of the cardiac index, with a maximum between the 6th and 8th hour (1.58 +/- 0.51 l.min-1.m-2 before treatment to 2.66 +/- 0,75 l.min-1.m-2 8 hours after, p less than 0.001) and a fall of total systemic resistance which declined from 2,478 +/- 421 dyn.s-1.cm-5 before treatment to 1,449 +/- 369 dyn.s-1.cm-5, p less than 0.001, 8 hours after, as well as an increase in the power of the left ventricule (from 2.80 +/- 0.8 before treatment to 4.73 +/- 1.2 kg/min 8 hours after, p less than 0.0001).(ABSTRACT TRUNCATED AT 250 WORDS)